Last updated: 2026-10-13 10:27:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Genprex, Inc. (GNPX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,64, with a market capitalisation of $2,23M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,53 to $1.210,00. This page covers its latest market performance, valuation, price trends and company information.
$2,23M | |
$2,70 | |
$855.795,60 | |
$2,53 | |
$2,69 | |
467,00 | |
259,41K | |
-- | |
$1.210,00 | |
$2,53 | |
-- | |
-- |
Genprex, Inc. (GNPX) is trading at $2,64 in pre-market trading as of 2026-10-13 09:18:00, down 1,71% ($0,05) from the previous close of $2,69
Pre-market trading shows how investors are pricing GNPX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Genprex, Inc. (GNPX) moved from $2,63 to $2,64, representing a gain of 0,53% ($0,01).
The stock traded between $2,55 and $2,93 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 200,23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,0%
GNPX is currently trading at $2,64, placing it 0,0% of the way from its 52-week low of $2,53 to its 52-week high of $1.210,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genprex, Inc. (GNPX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.